A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

David P. Greenberg, Robert E. Walker, Min Shi Lee, Keith S. Reisinger, Joel I. Ward, Ram Yogev, Mark M. Blatter, Sylvia H. Yeh, Ruth A Karron, Chithra Sangli, Lane Eubank, Kathleen L. Coelingh, Julie M. Cordova, Marilyn J. August, Harshvardhan B. Mehta, Wendy Chen, Paul M. Mendelman

Research output: Contribution to journalArticle

Abstract

Background. A phase 2 trial was conducted to assess in young infants the safety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). Methods. One hundred ninety-two healthy 2-month-old infants were randomized 1:1:1 to receive 1 × 10 5 median tissue culture infective dose (TCID 50) bPIV3 vaccine, 1 × 10 6 TCID 50 bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. Results. The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of ≥38.1°C after dose 2 only, occurring in 34% of the 1 × 10 5 TCID 50 group, 35% of the 1 × 10 6 TCID 50 group, and 12% of the placebo group (P5 TCID 50 group and 77% in the 1 × 10 6 TCID 50 group) (P = .46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1 × 10 5 TCID 50 group, 57% in the 1 × 10 6 TCID50 group, and 12% in the placebo group (P

Original languageEnglish (US)
Pages (from-to)1116-1122
Number of pages7
JournalJournal of Infectious Diseases
Volume191
Issue number7
DOIs
StatePublished - Apr 1 2005

Fingerprint

Bovine parainfluenza virus 3
Human parainfluenza virus 3
Vaccines
Placebos
Safety
Hemagglutination
Nose
Fever
Mothers
Interviews
Temperature
Antibodies
Serum

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Greenberg, D. P., Walker, R. E., Lee, M. S., Reisinger, K. S., Ward, J. I., Yogev, R., ... Mendelman, P. M. (2005). A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. Journal of Infectious Diseases, 191(7), 1116-1122. https://doi.org/10.1086/428092

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. / Greenberg, David P.; Walker, Robert E.; Lee, Min Shi; Reisinger, Keith S.; Ward, Joel I.; Yogev, Ram; Blatter, Mark M.; Yeh, Sylvia H.; Karron, Ruth A; Sangli, Chithra; Eubank, Lane; Coelingh, Kathleen L.; Cordova, Julie M.; August, Marilyn J.; Mehta, Harshvardhan B.; Chen, Wendy; Mendelman, Paul M.

In: Journal of Infectious Diseases, Vol. 191, No. 7, 01.04.2005, p. 1116-1122.

Research output: Contribution to journalArticle

Greenberg, DP, Walker, RE, Lee, MS, Reisinger, KS, Ward, JI, Yogev, R, Blatter, MM, Yeh, SH, Karron, RA, Sangli, C, Eubank, L, Coelingh, KL, Cordova, JM, August, MJ, Mehta, HB, Chen, W & Mendelman, PM 2005, 'A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy', Journal of Infectious Diseases, vol. 191, no. 7, pp. 1116-1122. https://doi.org/10.1086/428092
Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. Journal of Infectious Diseases. 2005 Apr 1;191(7):1116-1122. https://doi.org/10.1086/428092
Greenberg, David P. ; Walker, Robert E. ; Lee, Min Shi ; Reisinger, Keith S. ; Ward, Joel I. ; Yogev, Ram ; Blatter, Mark M. ; Yeh, Sylvia H. ; Karron, Ruth A ; Sangli, Chithra ; Eubank, Lane ; Coelingh, Kathleen L. ; Cordova, Julie M. ; August, Marilyn J. ; Mehta, Harshvardhan B. ; Chen, Wendy ; Mendelman, Paul M. / A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. In: Journal of Infectious Diseases. 2005 ; Vol. 191, No. 7. pp. 1116-1122.
@article{265ffbc7128148358c01322cafc7cb04,
title = "A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy",
abstract = "Background. A phase 2 trial was conducted to assess in young infants the safety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). Methods. One hundred ninety-two healthy 2-month-old infants were randomized 1:1:1 to receive 1 × 10 5 median tissue culture infective dose (TCID 50) bPIV3 vaccine, 1 × 10 6 TCID 50 bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. Results. The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of ≥38.1°C after dose 2 only, occurring in 34{\%} of the 1 × 10 5 TCID 50 group, 35{\%} of the 1 × 10 6 TCID 50 group, and 12{\%} of the placebo group (P5 TCID 50 group and 77{\%} in the 1 × 10 6 TCID 50 group) (P = .46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67{\%} in the 1 × 10 5 TCID 50 group, 57{\%} in the 1 × 10 6 TCID50 group, and 12{\%} in the placebo group (P",
author = "Greenberg, {David P.} and Walker, {Robert E.} and Lee, {Min Shi} and Reisinger, {Keith S.} and Ward, {Joel I.} and Ram Yogev and Blatter, {Mark M.} and Yeh, {Sylvia H.} and Karron, {Ruth A} and Chithra Sangli and Lane Eubank and Coelingh, {Kathleen L.} and Cordova, {Julie M.} and August, {Marilyn J.} and Mehta, {Harshvardhan B.} and Wendy Chen and Mendelman, {Paul M.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1086/428092",
language = "English (US)",
volume = "191",
pages = "1116--1122",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy

AU - Greenberg, David P.

AU - Walker, Robert E.

AU - Lee, Min Shi

AU - Reisinger, Keith S.

AU - Ward, Joel I.

AU - Yogev, Ram

AU - Blatter, Mark M.

AU - Yeh, Sylvia H.

AU - Karron, Ruth A

AU - Sangli, Chithra

AU - Eubank, Lane

AU - Coelingh, Kathleen L.

AU - Cordova, Julie M.

AU - August, Marilyn J.

AU - Mehta, Harshvardhan B.

AU - Chen, Wendy

AU - Mendelman, Paul M.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Background. A phase 2 trial was conducted to assess in young infants the safety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). Methods. One hundred ninety-two healthy 2-month-old infants were randomized 1:1:1 to receive 1 × 10 5 median tissue culture infective dose (TCID 50) bPIV3 vaccine, 1 × 10 6 TCID 50 bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. Results. The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of ≥38.1°C after dose 2 only, occurring in 34% of the 1 × 10 5 TCID 50 group, 35% of the 1 × 10 6 TCID 50 group, and 12% of the placebo group (P5 TCID 50 group and 77% in the 1 × 10 6 TCID 50 group) (P = .46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1 × 10 5 TCID 50 group, 57% in the 1 × 10 6 TCID50 group, and 12% in the placebo group (P

AB - Background. A phase 2 trial was conducted to assess in young infants the safety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). Methods. One hundred ninety-two healthy 2-month-old infants were randomized 1:1:1 to receive 1 × 10 5 median tissue culture infective dose (TCID 50) bPIV3 vaccine, 1 × 10 6 TCID 50 bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. Results. The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of ≥38.1°C after dose 2 only, occurring in 34% of the 1 × 10 5 TCID 50 group, 35% of the 1 × 10 6 TCID 50 group, and 12% of the placebo group (P5 TCID 50 group and 77% in the 1 × 10 6 TCID 50 group) (P = .46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1 × 10 5 TCID 50 group, 57% in the 1 × 10 6 TCID50 group, and 12% in the placebo group (P

UR - http://www.scopus.com/inward/record.url?scp=20144384490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144384490&partnerID=8YFLogxK

U2 - 10.1086/428092

DO - 10.1086/428092

M3 - Article

C2 - 15747247

AN - SCOPUS:20144384490

VL - 191

SP - 1116

EP - 1122

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -